ABCL vs NVS
AbCellera Biologics Inc. vs Novartis AG — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
| Metric | ABCL | NVS |
|---|
| AI Score |
66
|
75
|
| Price |
$9.75
|
$154.64
|
| P/E Ratio |
-18.07×
|
23.55×
|
| ROE |
-15.1%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
74.3%
|
| Debt / Equity |
0.15×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
90.0
|
57.7
|
| Beta |
1.191
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus NVS.
NVS leads by 9 points.
NVS scores 75/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical